Histologic features of graft-versus-host disease-associated angiomatosis: Insights into pathophysiology and treatment

J Am Acad Dermatol. 2020 Sep;83(3):914-917. doi: 10.1016/j.jaad.2019.12.058. Epub 2020 Jan 8.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use
  • Angiogenesis Inhibitors / pharmacology
  • Angiogenesis Inhibitors / therapeutic use
  • Angiomatosis / etiology*
  • Angiomatosis / pathology
  • Angiomatosis / therapy
  • Graft vs Host Disease / drug therapy
  • Graft vs Host Disease / etiology*
  • Graft vs Host Disease / pathology
  • Humans
  • Mechanistic Target of Rapamycin Complex 1 / antagonists & inhibitors
  • Sirolimus / pharmacology
  • Sirolimus / therapeutic use
  • Skin / blood supply
  • Skin / pathology*
  • Skin Diseases, Vascular / etiology*
  • Skin Diseases, Vascular / pathology
  • Skin Diseases, Vascular / therapy
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors

Substances

  • Adrenergic beta-Antagonists
  • Angiogenesis Inhibitors
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Mechanistic Target of Rapamycin Complex 1
  • Sirolimus